164 related articles for article (PubMed ID: 28587437)
1. Overexpression and correlation of HIF-2α, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progression.
Wu L; Zhang YS; Ye ML; Shen F; Liu W; Hu HS; Li SW; Wu HW; Chen QH; Zhou WB
Exp Ther Med; 2017 Jun; 13(6):3529-3534. PubMed ID: 28587437
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
Wu L; Zhou J; Zhou W; Huang XF; Chen Q; Wang W; Zhai L; Li S; Tang Z
Pathol Res Pract; 2021 Apr; 220():153270. PubMed ID: 33640712
[TBL] [Abstract][Full Text] [Related]
3. HIF-1α and HIF-2α: siblings in promoting angiogenesis of residual hepatocellular carcinoma after high-intensity focused ultrasound ablation.
Wu L; Fu Z; Zhou S; Gong J; Liu CA; Qiao Z; Li S
PLoS One; 2014; 9(2):e88913. PubMed ID: 24551189
[TBL] [Abstract][Full Text] [Related]
4. [Effects of hypoxia inducible factor-2α on promoting angiogenesis of residual hepatocellular carcinoma after high-intensity focused ultrasound ablation].
Wu L; Zhou W; Zhou S; Liu C; Li S
Zhonghua Gan Zang Bing Za Zhi; 2015 Feb; 23(2):112-7. PubMed ID: 25880977
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis.
Yang P; Yuan W; He J; Wang J; Yu L; Jin X; Hu Y; Liao M; Chen Z; Zhang Y
Hepatol Res; 2009 Dec; 39(12):1169-77. PubMed ID: 19788698
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Xu M; Xie XH; Xie XY; Xu ZF; Liu GJ; Zheng YL; Huang GL; Wang W; Zheng SG; Lü MD
Acta Radiol; 2013 Mar; 54(2):199-204. PubMed ID: 23171528
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer.
Onita T; Ji PG; Xuan JW; Sakai H; Kanetake H; Maxwell PH; Fong GH; Gabril MY; Moussa M; Chin JL
Clin Cancer Res; 2002 Feb; 8(2):471-80. PubMed ID: 11839666
[TBL] [Abstract][Full Text] [Related]
8. [Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof].
Zhang N; Gong K; Yang XY; Xin DQ; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(22):1526-9. PubMed ID: 16854277
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1α/VEGFA signalling in hepatocellular carcinoma.
Lin J; Cao S; Wang Y; Hu Y; Liu H; Li J; Chen J; Li P; Liu J; Wang Q; Zheng L
J Exp Clin Cancer Res; 2018 Jun; 37(1):113. PubMed ID: 29866133
[TBL] [Abstract][Full Text] [Related]
10. Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA.
Kong J; Kong J; Pan B; Ke S; Dong S; Li X; Zhou A; Zheng L; Sun WB
PLoS One; 2012; 7(5):e37266. PubMed ID: 22615958
[TBL] [Abstract][Full Text] [Related]
11. Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies.
Xiao C; Liu S; Ge G; Jiang H; Wang L; Chen Q; Jin C; Mo J; Li J; Wang K; Zhang Q; Zhou J
Front Pharmacol; 2023; 14():1086813. PubMed ID: 36814489
[TBL] [Abstract][Full Text] [Related]
12. Downregulation and pro-apoptotic effect of hypoxia-inducible factor 2 alpha in hepatocellular carcinoma.
Yang SL; Liu LP; Niu L; Sun YF; Yang XR; Fan J; Ren JW; Chen GG; Lai PB
Oncotarget; 2016 Jun; 7(23):34571-81. PubMed ID: 27119229
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma.
Zhu GQ; Tang YL; Li L; Zheng M; Jiang J; Li XY; Chen SX; Liang XH
Clin Cancer Res; 2010 Oct; 16(19):4732-41. PubMed ID: 20807755
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins.
Ioachim E; Michael M; Salmas M; Michael MM; Stavropoulos NE; Malamou-Mitsi V
Urol Int; 2006; 77(3):255-63. PubMed ID: 17033215
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma.
Bangoura G; Liu ZS; Qian Q; Jiang CQ; Yang GF; Jing S
World J Gastroenterol; 2007 Jun; 13(23):3176-82. PubMed ID: 17589895
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
17. Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma.
Bangoura G; Yang LY; Huang GW; Wang W
World J Gastroenterol; 2004 Feb; 10(4):525-30. PubMed ID: 14966910
[TBL] [Abstract][Full Text] [Related]
18. The correlation of expression levels of HIF-1α and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients' clinical outcome.
Yang SL; Liu LP; Jiang JX; Xiong ZF; He QJ; Wu C
Jpn J Clin Oncol; 2014 Feb; 44(2):159-67. PubMed ID: 24374892
[TBL] [Abstract][Full Text] [Related]
19. [Effect of HIF-2α on regulating CDCP1 to promote hepatocellular carcinoma metastasis].
Cao MQ; Gao JR; Huang JF; You AB; Guo ZG; Zhou HY; Fang F; Zhang W; Zhu XL; Zhang T
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):18-23. PubMed ID: 28104028
[No Abstract] [Full Text] [Related]
20. Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder.
Miyake M; Fujimoto K; Anai S; Ohnishi S; Kuwada M; Nakai Y; Inoue T; Matsumura Y; Tomioka A; Ikeda T; Tanaka N; Hirao Y
Oncol Rep; 2011 Mar; 25(3):653-60. PubMed ID: 21206978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
